This was a retrospective review of ED patients who underwent Rezūm™ by a single surgeon over 12 months. Patient age, presence of IPP, number of benign prostatic hyperplasia medications, International Prostate Symptom Score (IPSS), IPSS Quality of Life Index (QOL), uroflowmetry maximum flow rate (Qmax), and uroflowmetry average flow rate (Qavg) before and after Rezūm™ were obtained. Independent two-sample T-tests were used to compare preoperative and postoperative characteristics between patients with and without an IPP. Linear regression was performed to identify factors associated with postoperative Qmax or Qavg.
A total of 17 patients with ED who underwent Rezūm™ were identified, including 11 patients with an IPP. The median follow-up after Rezūm™ was 65 days. There were no significant differences in baseline demographics and clinical characteristics between patients with and without an IPP. Postoperative Qmax (10.9 mL/s vs 9.8 mL/s, p = 0.04) and Qavg (7.5 mL/s vs 6.0 mL/s, p = 0.03) were significantly higher in patients with an IPP compared to patients without an IPP. There were no factors associated with postoperative Qmax or Qavg on linear regression. Two patients without an IPP went into urinary retention, while no complications occurred in IPP patients.
Rezūm™ is a safe and effective procedure to perform in ED patients, particularly those with an IPP. IPP patients may experience greater increase in uroflowmetry rate compared to ED patients without an IPP.
方法:本研究是对由一名外科医生在12个月内接受Rezóm™治疗的ED患者的回顾性研究。患者年龄,IPP的存在,良性前列腺增生药物的数量,国际前列腺症状评分(IPSS)IPSS生活质量指数(QOL)尿流仪最大流量(Qmax),和尿流法平均流速(Qavg)之前和之后获得Rez_m™。使用独立的两个样本T检验来比较有和没有IPP的患者的术前和术后特征。进行线性回归以确定与术后Qmax或Qavg相关的因素。
结果:共确定了17例接受Rez_m™治疗的ED患者,包括11名IPP患者。Rezm™后的中位随访时间为65天。有和没有IPP的患者之间的基线人口统计学和临床特征没有显着差异。术后Qmax(10.9mL/svs9.8mL/s,p=0.04)和Qavg(7.5mL/svs6.0mL/s,与没有IPP的患者相比,IPP患者的p=0.03)明显更高。在线性回归上,没有与术后Qmax或Qavg相关的因素。两名没有IPP的患者出现尿潴留,IPP患者无并发症发生。
结论:Rezúm™是一种安全有效的ED患者手术,特别是那些有IPP的。与没有IPP的ED患者相比,IPP患者的尿流率可能会增加更多。